Table 6. Comparison of criteria measuring response to treatment*.
| Complete response | Partial response | Progressive disease | |
|---|---|---|---|
| Tumor size (%) | |||
| WHO [124] | Disappearance of all lesions | ≥50% ↓ | ≥25% ↑ |
| RECIST [136] | The disappearance of all lesions | ≥30% ↓ in the sum of diameters | ≥20% ↑ |
| mRECIST [137] | The disappearance of intratumoral arterial enhancement in all lesions | ≥30% ↓ in the sum of diameters of viable (enhance in arterial phase) target lesions | ≥20% ↑in the sum of diameters of viable (enhancing) target lesions |
| Choi [138] | The disappearance of all lesions | ≥10% ↓ OR≥15% ↓ in tumor density (CT) | ≥10% ↑ and Tumor density does not meet PR criteria |
| Modified Choi [137] | The disappearance of all lesions | ≥10% ↓ AND≥15% ↓ in tumor density (CT) | |
| Non-target Lesions | |||
| WHO | The disappearance of all lesions | - | ≥1 |
| RECIST | The disappearance of all lesions | Present | Unequivocal progression |
| mRECIST | The disappearance of intratumoral arterial enhancement | Intratumoral arterial enhancement in≥1 lesion | Unequivocal progression |
| Choi | The disappearance of all lesions | No obvious progression of non-measurable disease | New intratumoral nodules/↑ size of existing nodules |
| Modified Choi | The disappearance of all lesions | No obvious progression of non-measurable disease | New intratumoral nodules/↑ size of existing nodules |
| New lesions | |||
| WHO | - | - | ≥1 new lesion |
| RECIST | - | - | ≥1 new lesion |
| mRECIST | - | - | ≥1 new lesion |
| Choi | - | - | ≥1 new lesion |
| Modified Choi | - | - | ≥1 new lesion |
| Clinical | Choi and Modified Choi: SD- No symptomatic deterioration caused by tumor progression Clinical symptoms are not accounted for in other criteria |
||
| Overall response | |||
| WHO | Poorest response designation used | ||
| RECIST | Result of the combined assessment of target lesions, non-target lesions, and new lesions | ||
| mRECIST | Result of the combined assessment of target lesions, non-target lesions, and new lesions | ||
| Choi | Responders: ≥10% decrease in tumor size OR≥15% decrease in tumor density on CT | ||
| Non-responders: Do not meet the above criteria | |||
| Modified Choi | Responders: ≥10% decrease in tumor size OR≥15% decrease in tumor density on CT | ||
*
Stable Disease (SD) refers to any lesions that do not qualify under the criteria of CR/PR/PD. CT: Computed tomography; mRECIST: Modified Response evaluation criteria in solid tumors; RECIST: Response evaluation criteria in solid tumors; WHO: World Health Organization